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ABSTRACT 
Antiretroviral therapy (ART) has significantly reduced mortality in human immunodeficiency 
virus type 1 (HIV-1) infection, both in high- and low/middle-income countries (LMIC). However, 
the development of drug resistance following exposure to subtherapeutic concentrations of 
antiretrovirals (ARV) and transmitted drug resistance mutations (DRM) adversely affects the 
outcome of ART.  
In my thesis, drug resistance patterns of diverse HIV-1 subtypes were described, at both genotypic 
and phenotypic level. A high throughput sequencing (HTS) method was utilized to amplify and 
sequence the gag-pol of different HIV-1 subtypes for identification and quantification of DRM 
present in < 20% of the viral population. A novel bioinformatics pipeline was developed, 
MiDRMpol, which integrates genomic variations and mapping of minor populations with DRM. 
Phenotypic drug sensitivity assays were performed to study in vitro potency of newer ARV. Also, 
polymerase independent increase of virulence and replication competence of HIV-1, which may 
influence the outcome of ART, was studied.  
Paper I describes the pipeline, MiDRMpol, which can be used without any prior knowledge and 
does not require on-site bioinformatics support. The raw data from HTS in the fastq format are 
uploaded to get an easily readable format. One of the unique features, when compared to other 
available pipelines, is the FastUniq tool, which removes the duplicate reads generated by PCR, 
thus reducing the pseudo-bias of few variants. Another feature is the subtype-specific adaptation 
during the analysis. In Paper II and Paper III, I studied the potency of three newer ARV. 4′-
Ethynyl-2-fluoro-2′-deoxyadenosine (EFdA), a novel translocation defective reverse transcriptase 
inhibitor (RTI), was found to inhibit both wild-type and RTI resistant viruses efficiently in a 
subtype-independent manner. 
Similarly, second-generation integrase strand inhibitors (INSTI) cabotegravir (CAB) and 
bictegravir (BIC) were shown to have equal or higher potency against non-B subtypes as 
compared to HIV-1B. This confirms the suitability of these drugs for use in countries dominated 
by non-B subtypes. In Paper IV, I observed that a PYxE insertion in the gag plays a role in 
increased virulence and replication capacity in HIV-1C viruses and seems to be associated with 
suboptimal CD4
+
 T-cell gain following ART initiation. Even though there was no effect of PYxE 
or PTAPP on the susceptibility to 20 ARVs, the enhanced replication capacity might increase the 
time to reach viral suppression during ART and thereby increased the risk for the virus to develop 
DRM. 
In conclusion, identification and quantification of DRM at frequencies <20% is a major hurdle in 
current ART monitoring, and our MiDRMpol facilitates the analysis of such HTS data. However, 
we found that also polymerase independent mutations which increase the replication 
capacity/virulence of HIV-1 may influence the outcome of ART. The new ARVs EFdA, CAB, 
and BIC suppress the viral load in vitro in a subtype independent manner. This is important since 
if not all subtypes are suppressed efficiently the risk of a global increase of acquired DRM would 
be further increased.  
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